title: Pyoderma gangrenosum associated with ulcerative colitis: response to infliximab.
abstract: Pyoderma gangrenosum is an extraintestinal manifestation of inflammatory bowel disease that can be therapeutically troublesome. We comment on the case of a patient with clinically inactive ulcerative colitis who progressively developed necrotic lesions on both tibial aspects of his legs, which corresponded both clinically and histologically to pyoderma gangrenosum. Treatment with steroids and azathioprine could not control this complication. A single dose of infliximab 5 mg/kg was given, achieving an impressive response of the skin lesions followed by complete healing 3 months later. Infliximab can be useful in the management of refractory extraintestinal manifestations of inflammatory bowel disease.
authors.affiliation: Services of Gastroenterology, University Hospital Ramón y Cajal, Madrid, Spain.
authors.forename: A
authors.initials: A
authors.lastname: López San Román
authors.forename: F
authors.initials: F
authors.lastname: Bermejo
authors.forename: I
authors.initials: I
authors.lastname: Aldanondo
authors.forename: E
authors.initials: E
authors.lastname: Carrera
authors.forename: D
authors.initials: D
authors.lastname: Boixeda
authors.forename: E
authors.initials: E
authors.lastname: Muñoz Zato
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003093:Colitis, Ulcerative / Q000150:complications / Q000188:drug therapy*; D003879:Dermatologic Agents / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D017511:Pyoderma Gangrenosum / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D000069285:Infliximab